ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Therapy, alternative"

  • Abstract Number: 0047 • ACR Convergence 2022

    Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis

    Thomas Hoyler, Jeremy Scherer, Maxime Bulle, Conrad Wyss, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland

    Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…
  • Abstract Number: 2260 • ACR Convergence 2022

    Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes

    Shivmurat Yadav1, Monika Niewiadomska1, Lynsie Morris2, Taylor Conner2, Jessica Lumry2, Sanique South3, Emmaline Prinz2, Matlock Jeffries2, Timothy Griffin2, Stavros Stavrakis1 and Mary Beth Humphrey1, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Oklahoma Medical Research Foundation, Okahoma City, OK

    Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting over 32.5 million US adults and characterized by pain, stiffness, swelling and functional disability.…
  • Abstract Number: 0474 • ACR Convergence 2022

    Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients

    Fabricio Benavides Villanueva1, Cristina Corrales1, Javier Loricera2, Monica Calderón-Goercke1, Clara Moriano3, Santos Castañeda4, FRANCISCO JAVIER NARVAEZ5, Vicente Aldasoro6, Olga Maiz7, Rafael Melero8, Juan Ignacio Villa9, Paloma Vela-Casampere10, Susana Romero Yuste11, José Luis Callejas12, Eugenio De Miguel13, Eva Galíndez-Agirregoikoa14, Francisca Sivera15, Jesús Carlos Fernández-López16, Carles Galisteo17, Ivan Ferraz Amaro18, JULIO SANCHEZ MARTIN1, Lara Sánchez-Bilbao1, Jose Luis Hernández1, Miguel Angel Gonzalez Gay19 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Complejo Asistencial Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 7Hospital Universitario de Donostia, San Sebastián, Spain, 8Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital Sierrallana, Torrelavega, Spain, 10Hospital General Universitario Alicante, Alicante, Spain, 11Complexo Hospitalario Universitario, Pontevedra, Spain, 12Hospital San Cecilio, Granada, Andalucia, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 16Complejo H. Universitario de A Coruña, A Coruña, Spain, 17Hospital Parc Tauli,, Sabadel, Spain, 18Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 19Hospital Universitario Marques de Valdecilla, Lugo, Spain

    Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…
  • Abstract Number: PP07 • ACR Convergence 2022

    Remissions and Vigilance

    Michael Scepaniak, Cockeysville, MD

    Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
  • Abstract Number: 0589 • ACR Convergence 2022

    Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation

    Carlos Pérez-Sánchez1, Adrián Llamas Urbano2, Tomás Cerdó2, Laura Muñoz-Barrera1, Ismael Sánchez-Pareja2, Luz Marina Sánchez-Mendoza3, Nuria Barbarroja1, María Carmen Ábalos-Aguilera4, Juan Antonio Moreno5, María isabel Burón6, José Antonio González-Reyes5, Pilar Font1, Jerusalem Calvo-Gutierrez2, Marta Rojas-Gimenez1, Eduardo Collantes1, Alejandro Escudero-Contreras2, José Manuel Villalba-Montoro6 and Chary Lopez-Pedrera1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, Córdoba, Spain, 4Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 5Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Córdoba, Spain, 6Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain

    Background/Purpose: This study aimed to: 1- Evaluate the levels of NAD+ and gene transcripts involved in its metabolism in Rheumatoid Arthritis (RA) patients. 2- Analyse…
  • Abstract Number: 0597 • ACR Convergence 2022

    TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts

    Farheen Sultan Shaikh, Anil Singh, Paul Panipinto and Salahuddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist…
  • Abstract Number: 0626 • ACR Convergence 2022

    Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model

    Meena Afroze Shanta1, Farheen Sultan Shaikh2, Bhanupriya Madarampalli3 and Salahuddin Ahmed2, 1College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, 2Washington State University, Spokane, WA, 3University of Washington, Bellevue, WA

    Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…
  • Abstract Number: 0690 • ACR Convergence 2022

    The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis

    Ajay Tambralli1, Alyssa Harbaugh1, Christine Rysenga1, Kaitlyn Sabb1, Srilakshmi Yalavarthi1, Claire Hoy1, Yu (Ray) Zuo1 and Jason S Knight2, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
  • Abstract Number: 0909 • ACR Convergence 2022

    Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera1, Tomás Cerdó2, Maria Luque-Tevar3, Pilar Font1, Montserrat Romero-Gomez2, Desiree Ruiz-Vilchez4, Sara Remuzgo-Martinez5, Raquel Lopez Mejias6, María Carmen Ábalos-Aguilera7, Rafaela Ortega-Castro1, José Perez-Venegas8, Mª Dolores Ruiz-Montesinos8, Carmen Dominguez8, Carlos Rodriguez-Escalera9, Carmen Romero-Barco9, Antonio Fernandez-Nebro10, Natalia Mena Vazquez10, Jose Luis Marenco11, Julia Uceda Montañez11, Charo Santos12, Nuria Barbarroja1, Mª Angeles Aguirre13, Alejandro Escudero-Contreras2, Eduardo Collantes1, Miguel Ángel González-Gay14 and Carlos Pérez-Sánchez1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, 3IMIBIC, Córdoba, Spain, 4Reina Sofia University Hospital, Cordoba, Cordoba, Spain, 5Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6IDIVAL, Santander, Spain, 7Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, 8Virgen Macarena University Hospital, Sevilla, Spain, 9Virgen de la Victoria Hospital, Málaga, Spain, 10Regional University Hospital of Málaga, Málaga, Spain, 11Virgen de Valme University Hospital, Sevilla, Spain, 12Virgen de Valme University Hospital, Málaga, Spain, 13Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 14Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
  • Abstract Number: 1061 • ACR Convergence 2022

    Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up

    andrea cere, Emanuele Gotelli, Lercara Adriano, Carmen Pizzorni, sabrina Paolino, Alessandri Elisa, Maurizio Cutolo and Alberto Sulli, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: Recent studies proved that aminaphtone is an effective treatment for Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc). Laser Speckle Contrast Analysis (LASCA) further…
  • Abstract Number: 1074 • ACR Convergence 2022

    Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis

    Berengere Molina1, Maria Letizia Urban2, Roberto Padoan3, Pavel Novikov4, Camille Taillé5, Marco Caminati6, Christine Christides7, nicolas schleinitz8, Laura Moi9, Vincent Cottin10, bertrand godeau11, Laurence Bouillet12, Paolo Fraticelli13, Ann Knight14, Jan Walter Schroeder15, Sylvain Marchand-Adam16, Helder Gil17, Elena Gelain18, Giacomo Emmi2 and Benjamin Terrier19, 1Department of Internal Medicine, Cochin Hospital, Paris, France, 2Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 3University of Padova, Padova, Italy, 4Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, 5Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, 6Verona University Hospital, University of Verona, Verona, Italy, 7Avignon hospital, Avignon, France, 8Aix Marseille university, AP-HM, Marseille, France, 9Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, 10Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 11Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, 12Grenoble University Hospital, Grenoble, France, 13Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, 14Akademiska sjukhuset, Uppsala, Sweden, 15ASST GOM Niguarda, Milano, Italy, 16Tours University Hospital, Tours, France, 17Besancon University Hospital, Besançon, France, 18Meyer Children’s University Hospital of Firenze, Florence, Italy, 19National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
  • Abstract Number: 1079 • ACR Convergence 2022

    Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital

    Fabricio Benavides Villanueva1, Cristina Corrales1, Vanesa Calvo Río2, Javier Loricera3, Nuria Aviles4, Juan M Blanco Madrigal5, Santos Castañeda6, Miguel Angel Gonzalez Gay7 and Ricardo Blanco3, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Valdecilla Hospital, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Perpetuo Socorro, Albacete, Spain, 5Basurto University Hospital, Bilbao, Spain, 6Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 7Hospital Universitario Marques de Valdecilla, Lugo, Spain

    Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
  • Abstract Number: 1107 • ACR Convergence 2022

    Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study

    Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China

    Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
  • Abstract Number: 1375 • ACR Convergence 2022

    Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis

    zhaoling wang1, meiping lu2 and qi zheng1, 1Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 2Children’s Hospital of Zhejiang University Medical School, Zhejiang, China

    Background/Purpose: To evaluate the short-term efficacy and safety of baricitinib in children withrefractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. Methods: A monocentric…
  • Abstract Number: 1723 • ACR Convergence 2022

    CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model

    Annegret Van der Aa1, Simon Tessier1, Jean-Philippe Herbeuval2 and Joël Crouzet1, 1Ermium Therapeutics SAS, Paris, France, 2CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences